LAVA Therapeutics (NASDAQ:LVTX) Short Interest Update

LAVA Therapeutics (NASDAQ:LVTX) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totalling 45,400 shares, a decline of 20.9% from the August 15th total of 57,400 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily volume of 69,300 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Ratings Changes

A number of research analysts have recently weighed in on LVTX shares. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of LAVA Therapeutics in a report on Friday, June 28th. JMP Securities reaffirmed a “market outperform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Wednesday, August 21st.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC raised its stake in shares of LAVA Therapeutics (NASDAQ:LVTX) by 328.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 60,000 shares of the company’s stock after purchasing an additional 46,000 shares during the period. Pathway Financial Advisors LLC’s holdings in LAVA Therapeutics were worth $108,000 as of its most recent SEC filing.

LAVA Therapeutics Stock Up 2.1 %

Shares of LAVA Therapeutics stock opened at $1.72 on Monday. The stock has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.39. LAVA Therapeutics has a 52-week low of $1.13 and a 52-week high of $6.47. The firm has a market cap of $43.60 million, a price-to-earnings ratio of -1.59 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.39 and a quick ratio of 6.39.

LAVA Therapeutics (NASDAQ:LVTX) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 48.53%. On average, equities research analysts expect that LAVA Therapeutics will post -1.28 earnings per share for the current fiscal year.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.